| Title |
Emerging utility of once-weekly exenatide in patients with type 2 diabetes
|
|---|---|
| Published in |
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, October 2015
|
| DOI | 10.2147/dmso.s69354 |
| Pubmed ID | |
| Authors |
Aditya Goud, Jixin Zhong, Sanjay Rajagopalan |
| Abstract |
Type 2 diabetes mellitus (T2DM) is a major risk factor for the development of cardiovascular disease (CVD). Due to the ever increasing incidence of both T2DM and CVD and coexistence of these disorders, numerous agents have been developed over the years to target complications. We focus on the efficacy and safety perspective of a long-acting formulation of the glucagon-like peptide-1 analog exenatide. Our review focuses on the various landmark trials, efficacy, safety profile, and patient perspectives of weekly exenatide that delineates its current and future role in the treatment of patients with T2DM and CVD. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 19 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 19 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 4 | 21% |
| Student > Bachelor | 4 | 21% |
| Other | 2 | 11% |
| Researcher | 2 | 11% |
| Professor | 1 | 5% |
| Other | 1 | 5% |
| Unknown | 5 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 26% |
| Nursing and Health Professions | 3 | 16% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 11% |
| Immunology and Microbiology | 1 | 5% |
| Agricultural and Biological Sciences | 1 | 5% |
| Other | 2 | 11% |
| Unknown | 5 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 October 2015.
All research outputs
#20,011,936
of 25,457,858 outputs
Outputs from Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
#792
of 1,184 outputs
Outputs of similar age
#196,464
of 287,079 outputs
Outputs of similar age from Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
#9
of 13 outputs
Altmetric has tracked 25,457,858 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,184 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.5. This one is in the 29th percentile – i.e., 29% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 287,079 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.